Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Opioid receptor-coupled second messenger systems.

S R Childers1

  • 1Department of Physiology and Pharmacology, Bowman Gray School of Medicine, Winston-Salem, NC 27103.

Life Sciences
|January 1, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

High and low doses of cocaine intake are differentially regulated by dopamine D2 receptors in the ventral tegmental area and the nucleus accumbens.

Neuroscience letters·2018
Same author

Regional differences in mu and kappa opioid receptor G-protein activation in brain in male and female prairie voles.

Neuroscience·2015
Same author

Colocalization of mu-opioid receptors and activated G-proteins in rat cingulate cortex.

The Journal of pharmacology and experimental therapeutics·2001
Same author

mu Opioid receptor-mediated G-protein activation by heroin metabolites: evidence for greater efficacy of 6-monoacetylmorphine compared with morphine.

Biochemical pharmacology·2001
Same author

Synthesis of 2beta-acyl-3beta-(substituted naphthyl)-8-azabicyclo[3.2.1]octanes and their binding affinities at dopamine and serotonin transport sites.

Journal of medicinal chemistry·2001
Same author

Functional and anatomical localization of mu opioid receptors in the striatum, amygdala, and extended amygdala of the nonhuman primate.

The Journal of comparative neurology·2001
Same journal

Steroidal alkaloid H89712 ameliorates neuroinflammation and memory deficits: Enhancing cerebral oxidative phosphorylation in APP/PS1 mice.

Life sciences·2026
Same journal

Targeting PARP1-dependent parthanatos in Alzheimer's disease: Mechanisms and therapeutic opportunities.

Life sciences·2026
Same journal

The emerging role of NAT10-mediated N4-acetylcytidine modification of RNA in bone diseases: Current frontiers and future challenges.

Life sciences·2026
Same journal

Overactivated bradykinin-B2 receptor promotes type a aortic dissection by inducing endothelial dysfunction: Therapeutic effect of icatibant.

Life sciences·2026
Same journal

Gut microbiota and metabolites in remodeling the tumor microenvironment and regulating immunotherapeutic efficacy in colorectal cancer.

Life sciences·2026
Same journal

A CD31-derived cytoplasmic ITIM peptide enhances epidermal and dermal regeneration in cutaneous wound repair.

Life sciences·2026
See all related articles

Opioid receptors (mu, delta, kappa) interact with G-proteins and inhibit adenylyl cyclase, common pathways potentially involved in opioid tolerance development.

Area of Science:

  • Pharmacology
  • Neuroscience
  • Molecular Biology

Background:

  • Pharmacological data indicate distinct opioid receptor types (mu, delta, kappa).
  • Opioid receptors share common properties in coupling to second messenger systems.
  • G-protein coupling is a conserved mechanism across opioid receptor subtypes.

Purpose of the Study:

  • To elucidate the common signaling pathways of different opioid receptor types.
  • To investigate the role of G-protein coupling and second messenger systems in opioid tolerance.

Main Methods:

  • Agonist binding assays to assess G-protein interactions.
  • Measurement of GTPase activity in response to opioid agonists.
  • Adenylyl cyclase inhibition assays in brain membranes and cell cultures.

Related Experiment Videos

Main Results:

  • All opioid receptor types (mu, delta, kappa) are coupled to G-proteins.
  • Agonist binding is reduced by guanine nucleotides, confirming G-protein interaction.
  • Opioid receptor activation inhibits adenylyl cyclase activity.
  • Chronic opioid agonist treatment suggests a role for receptor-G-protein coupling in tolerance.

Conclusions:

  • Opioid receptors utilize conserved G-protein-mediated signaling pathways, including adenylyl cyclase inhibition.
  • The coupling of opioid receptors to G-proteins and second messenger effectors is implicated in the development of opioid tolerance.